Article Sidebar

PDF
Date Published: 28/01/2025
Abstract Views: 8
Views PDF: 4
DOI: https://doi.org/10.56535/jmpm.v50i1.1057
Issue
Vol. 50 No. 1 (2025): TẠP CHÍ Y DƯỢC HỌC QUÂN SỰ SỐ 1 - 2025
Section
Articles
How to Cite
Phan, T. H. T., Nguyễn, T. T., & Chy, K. (2025). SURVEY ON SOME CLINICAL AND SUBCLINICAL CHARACTERISTICS IN PRIMARY EXTRANODAL NON-HODGKIN LYMPHOMA PATIENTS. Journal of Military Pharmaco-medicine, 50(1), 131-141. https://doi.org/10.56535/jmpm.v50i1.1057

SURVEY ON SOME CLINICAL AND SUBCLINICAL CHARACTERISTICS IN PRIMARY EXTRANODAL NON-HODGKIN LYMPHOMA PATIENTS

Thị Hoài Trang Phan1, , Thị Thảo Nguyễn1, Kimheng Chy2
1 Bộ môn - Trung tâm Nội Dã chiến, Bệnh viện Quân y 103, Học viện Quân y
2 Bệnh viện Quân y Trung ương 179 Campuchia

Main Article Content

Abstract

Objectives:  To evaluate some clinical and subclinical features of primary extranodal non-Hodgkin lymphoma (pENL) patients. Methods: A prospective, cross-sectional descriptive study was conducted on 47 patients with pENL in the Field Internal Medicine Center, Military Hospital 103. Results and conclusions: The average age was 60.51 ± 15.66 years, male/female ratio was 1.35/1. The disease onset is usually less than 3 months. Common symptoms: B symptoms: 40.4%, anemia: 53.2%. The most common damage site is in the digestive tract: 34.8%. Diffuse large B-cell histopathology predominates with 70.2%. Most patients are in the low-risk prognostic group with a rate of 59.6%. There is a correlation between the disease prognostic indicators and onset of the disease, histopathological type, hypoalbuminemia and serum β2M level >2,22 (µg/ml) (p< 0.05).

Article Details

Keywords

primary extranodal nonHodgkin lymphoma, clinical and subclinical features

References

1. Evans Linda S, Hancock Barry W. Non-Hodgkin lymphoma. The Lancet. 2003; 362(9378):139-146.
2. Milano Anthony F. Non-hodgkin lymphoma - nodal and extranodal: 20-year comparative mortality, survival & biologic behavior analysis by age, sex, race, stage, cell morphology/ histology, cohort entry time-period and disease duration: A systematic review of 384,651 total nhl cases including 261,144 nodal and 123,507 extranodal cases for diagnosis years 1975-2016: (SEER*Stat 8.3.6). Journal of Insurance Medicine. 2023; 50(1):1-35.
3. Nghiêm Thị Minh Châu. Nghiên cứu đặc điểm lâm sàng, cận lâm sàng u lympho ác tính non-Hodgkin nguyên phát ngoài hạch tại Bệnh viện Quân y 103 giai đoạn 2008 - 2014. Tạp chí Y Dược học Quân sự. 2014; 8:106-111.
4. d'Amore Francesco, Christensen Bjarne E, Brincker Hans, et al. Clinicopathological features and prognostic factors in extranodal non-Hodgkin lymphomas. European Journal of Cancer and Clinical Oncology. 1991; 27(10):1201-1208.
5. Narang Vikram, Steffi, Singh Aminder, et al. Primary extranodal non-hodgkin lymphomas: A first tertiary care experience from Punjab, North India. South Asian J Cancer. 2020; 9(04):230-232.
6. Shen H, Jiang L, Nie L, et al. prognostic analysis of patients with primary extranodal lymphoma: A retrospective study. Cancer Manag Res. 2021; 13:2171-2180.
7. Neal RD, Tharmanathan P, France B, et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br J Cancer. 2015; 112, 1(1):92-107.
8. Dapkevičiūtė A, Šapoka V, Martynova E, et al. Time from symptom onset to diagnosis and treatment among haematological malignancies: Influencing factors and associated negative outcomes. Medicina (Kaunas). 2019; 55(6).
9. Toki H, Okabe K, Kimura Y, et al. Difference in prognosis between T- and B-cell lymphomas: Clinical study at Shikoku Cancer Center Hospital. Jpn J Clin Oncol. 1986; 16(1):41-48.
10. Bento L, Díaz-López A, Barranco G, et al. New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish lymphoma group experience (GELTAMO). Br J Haematol. 2020; 188(6):888-897.